RCS - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

15/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250415:nRSO9805Ea&default-theme=true

RNS Number : 9805E  Physiomics PLC  15 April 2025

15 April 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by Numab Therapeutics

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract with
its long-standing client, Numab Therapeutics AG.

The project will involve the application of modelling and simulation
techniques to inform pre-clinical development of a multi-specific antibody
designed to activate anti-tumor immune responses for the treatment of cancer.
This project is expected to complete within the next two months.

This latest collaboration extends the history of the Company working with
Numab Therapeutics in applying Model Informed Drug Development to address
complex challenges with mathematical modelling and simulation techniques.

Dr Peter Sargent, CEO of Physiomics, commented:

"This new contract marks another step in our long-term collaboration with
Numab Therapeutics, reinforcing our role as a trusted partner to provide
specialist modelling support to inform critical stages of drug development. We
are delighted to be working once again with the Numab team."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUUACUPAGQC